• Multidisciplinary team (26 people) US
antiemetic drug development is
still very active, and newer NK1
RAs have recently come on to
the market besides the initial
one, that of aprepitant (and its
IV formulation, fosaprepitant),
rolapitant, and netupitant
(which is only available in fixed
combination with palonosetron
in NEPA). There are multiple
trials published for each of these
agents and the information that
is becoming available on their
antiemetic efficacy as well as
that of other classes of drugs is multiplying rapidly. 14 Because
there are so many antiemetic
treatment options, it is difficult
for some clinicians to identify
the best evidence available,
as it would need a significant
amount of time and dedication
to the particular symptoms on
an ongoing basis, which is not
feasible as the management
of these two symptoms is only
a small part of the clinicians’
workload, who often work in very
busy clinics. Also, some clinicians
change their practice very slowly
Updated
annually. Last
update: 2018
hospitalpharmacyeurope.com | 2018 | 23